Phase II Study of Inotuzumab Ozogamicin in Patients with B-cell Lineage Acute Lymphocytic Leukemia with Positive Minimal Residual Disease
MD Anderson Study Status
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease. Inotuzumab ozogamicin is a monoclonal antibody called inotuzumab linked to a toxic agent called ozogamicin. Inotuzumab ozogamicin attaches to B cell-specific CD22 cancer cells in a targeted way and kills them.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplant Recipient, B Acute Lymphoblastic Leukemia, Minimal Residual Disease, Philadelphia Chromosome Positive, Recurrent B Acute Lymphoblastic Leukemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.